StockWatch
·
Biotechnology: Pharmaceutical Preparations
LegalNov 19, 2026, 04:07 PM

Oramed Pharmaceuticals Settles Stockholder Bylaw Lawsuit for $125,000

AI Summary

Oramed Pharmaceuticals Inc. has resolved a purported class action lawsuit challenging its bylaws regarding stockholder action by written consent. The company agreed to amend its bylaws, which mooted the action. Subsequently, the court dismissed the case, and Oramed agreed to pay plaintiff's counsel $125,000 in attorneys' fees and expenses without admitting fault.

Key Highlights

  • Oramed Pharmaceuticals Inc. faced a class action lawsuit challenging its bylaws on stockholder action by written consent.
  • The company amended its bylaws to resolve the litigation.
  • The lawsuit was dismissed by the court.
  • Oramed agreed to pay $125,000 in attorneys' fees and expenses to plaintiff's counsel.